An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016

(2019) Rajesh Sharma   Breast Cancer

The global and regional survival rate of women with breast cancer: A systematic review and meta-analysis

(2019) Khadije Maajani et al.   Clinical Breast Cancer

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade

(2019) Aleix Prat et al.   JNCI-Journal of the National Cancer Institute

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2+ breast cancer cells

(2019) Carolina D'Alesio et al.   Biology Open

RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells

(2018) Yoshihide Mitsuda et al.   Scientific Reports

Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells

(2018) Harry Lee et al.   Scientific Reports

Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California

(2018) Li Tao et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

(2018) Sarah Croessmann et al.   CLINICAL CANCER RESEARCH

ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling

(2018) Matthias Christgen et al.   GENES CHROMOSOMES & CANCER

Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer

(2018) Ji Lu et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

AKT signaling in ERBB2-amplified breast cancer

(2016) F. Javier Carmona et al.   PHARMACOLOGY & THERAPEUTICS

ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast

(2016) Zheng Ping et al.   Oncotarget

ErbB2 signaling activates the Hedgehog pathway via PI3K–Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts

(2015) Maxim Kebenko et al.   CELLULAR SIGNALLING

Cancer Signature Investigation:ERBB2(HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary

(2015) Jennifer Shih et al.   Journal of the National Comprehensive Cancer Network

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation

(2015) Saranya Chumsri et al.   Journal of the National Comprehensive Cancer Network

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors

(2014) Elizabeth S. Yeh et al.   BREAST CANCER RESEARCH AND TREATMENT

Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent Pathway

(2014) Rosa Martín-Pérez et al.   CANCER RESEARCH

Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors

(2014) QINGFEI WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

Role of ErbB2 mediated AKT and MAPK pathway in gall bladder cell proliferation induced by argemone oil and butter yellow

(2012) Vivek Mishra et al.   CELL BIOLOGY AND TOXICOLOGY

Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients

(2012) Sang Hyub Lee et al.   PATHOLOGY INTERNATIONAL

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway

(2011) Sonyo Shin-Kang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA

(2011) G Paroni et al.   ONCOGENE

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

(2011) Richard Greil et al.   ONKOLOGIE

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

(2010) C. Vogel et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

(2009) Xiaolei Zhou et al.   BREAST CANCER RESEARCH AND TREATMENT